Contact us

877-469-1TRM
424-208-8866

Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia Subjects ≥ 65

A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

For Eligibility criteria and additional information, visit Clinical Trials.gov.

Patient Population Investigational Product(s) Phase Status
Acute Myeloid Leukemia, Acute Myelogenous Leukemia Lenalidomide II Open and Accruing